Customize your JAMA Network experience by selecting one or more topics from the list below.
Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA. 2009;302(11):1202–1209. doi:10.1001/jama.2009.1348
Author Affiliations: The Cancer Institute of New Jersey (Drs Lu-Yao, Moore, Shih, Lin, DiPaola, and Yao); Department of Medicine, Robert Wood Johnson Medical School (Drs Lu-Yao, DiPaola, and Yao) and Department of Biostatistics, The School of Public Health (Drs Moore, Shih, and Lin), University of Medicine and Dentistry of New Jersey, Piscataway; Department of Surgery (Urology), University of Connecticut, Farmington (Dr Albertsen); The Dean and Betty Gallo Prostate Cancer Center (Drs Lu-Yao and DiPaola), Medical Practices Evaluation Center (Dr Barry and Ms Walker-Corkery), and Department of Radiation Oncology (Dr Zietman), Massachusetts General Hospital, Boston; Department of Surgery, Harvard Medical School, Boston (Dr O’Leary); and Schering-Plough Research Institute, Kenilworth, New Jersey (Dr Yao).
Context Most newly diagnosed prostate cancers are clinically localized, and major treatment options include surgery, radiation, or conservative management. Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)–era data on outcomes with this approach.
Objective To evaluate the outcomes of clinically localized prostate cancer managed without initial attempted curative therapy in the PSA era.
Design, Setting, and Participants A population-based cohort study of men aged 65 years or older when they were diagnosed (1992-2002) with stage T1 or T2 prostate cancer and whose cases were managed without surgery or radiation for 6 months after diagnosis. Living in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program, the men were followed up for a median of 8.3 years (through December 31, 2007). Competing risk analyses were performed to assess outcomes.
Main Outcome Measures Ten-year overall survival, cancer-specific survival, and major cancer related interventions.
Results Among men who were a median age of 78 years at cancer diagnosis, 10-year prostate cancer-specific mortality was 8.3% (95% confidence interval [CI], 4.2%-12.8%) for men with well-differentiated tumors; 9.1% (95% CI, 8.3%-10.1%) for those with moderately differentiated tumors, and 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors. The corresponding 10-year risks of dying of competing causes were 59.8% (95% CI, 53.2%-67.8%), 57.2% (95% CI, 52.6%-63.9%), and 56.5% (95% CI, 53.6%-58.8%), respectively. Ten-year disease-specific mortality for men aged 66 to 74 years diagnosed with moderately differentiated disease was 60% to 74% lower than earlier studies: 6% (95% CI, 4%-8%) in the contemporary PSA era (1992-2002) compared with results of previous studies (15%-23%) in earlier eras (1949-1992). Improved survival was also observed in poorly differentiated disease. The use of chemotherapy (1.6%) or major interventions for spinal cord compression (0.9%) was uncommon.
Conclusions Results following conservative management of clinically localized prostate cancer diagnosed from 1992 through 2002 are better than outcomes among patients diagnosed in the 1970s and 1980s. This may be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care.
Create a personal account or sign in to: